New Diagnostic Combines Fast Imaging Hardware with Data Analysis to Indicate Blood Clotting in COVID-19 Patients

By LabMedica International staff writers
Posted on 14 Dec 2021

Illustration

Physicians treating coronavirus infections have a new diagnostic that could help identify COVID-19 patients at a risk of organ failure.

In a study of microvascular thrombosis in COVID-19 patients, researchers at the University of Tokyo (Tokyo, Japan) and University of Virginia (Charlottesville, VA, USA) conducted data and image analysis of the patients’ blood samples. They found an unusual presence of excessive platelet aggregation – an early indicator of microvascular thrombosis – in close to 90% of the patients.

Computing image features allowed the team to quantify individual platelets and platelet aggregates. An increase in platelet aggregates was correlated with worsening patient condition; moreover, they found strong links between the concentration of platelet aggregates and the severity, mortality, respiratory condition and vascular endothelial dysfunction level of the patients in the study. The technology generates data within a matter of hours and could potentially permit medical staff to determine patients at risk for micro thrombosis-related issues.

The team now plans to continue this line of research, expanding computational analysis to other aspects of the images. For the moment, the merger of medicine, hardware engineering, optical imaging, mathematical modeling and data science has strengthened medical professionals’ confidence in their ability to improve COVID-19 patient outcomes.

“People knew from autopsy data that multi-organ microvascular thrombosis is a factor in COVID-19 related deaths, but the underlying physiology with regards to platelet aggregates and morphology was an unknown,” said Gustavo Rohde, UVA professor of biomedical engineering and electrical and computer engineering. “Now we have a new technology that combines fast imaging hardware with data analysis to measure and characterize platelet morphology distribution from COVID-19 patient blood samples.”

“If you have to look at one thing as far as platelets are concerned, so far aggregate concentration seems to be the key indicator of a patient’s risk of thrombosis and its complications,” Rohde added. “We will need these types of measurements going forward, to monitor disease progression, to study complications from long-haul COVID-19, and to develop and test drugs that can prevent the blood clots from forming in the first place.”

Related Links:
University of Tokyo
University of Virginia